Related Experiment Videos
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Nico Jacobi1, Rita Seeboeck2, Elisabeth Hofmann3
1Research Institute for Applied Bioanalytics and Drug Development, IMC University of Applied Sciences Krems, Krems an der Donau 3500, Austria. nico.jacobi@fh-krems.ac.at.
Abstract:
ErbB family members represent important biomarkers and drug targets for modern precision therapy. They have gained considerable importance as paradigms for oncoprotein addiction and personalized medicine. This review summarizes the current understanding of ErbB proteins in cell signalling and cancer and describes the molecular rationale of prominent cases of ErbB oncoprotein addiction in different cancer types. In addition, we have highlighted experimental technologies for the development of innovative cancer cell models that accurately predicted clinical ErbB drug efficacies. In the future, such cancer models might facilitate the identification and validation of physiologically relevant novel forms of oncoprotein and non-oncoprotein addiction or synthetic lethality. The identification of genotype-drug response relationships will further advance personalized oncology and improve drug efficacy in the clinic. Finally, we review the most important drugs targeting ErbB family members that are under investigation in clinical trials or that made their way already into clinical routine. Taken together, the functional characterization of ErbB oncoproteins have significantly increased our knowledge on predictive biomarkers, oncoprotein addiction and patient stratification and treatment.
Insights
This review explores ErbB proteins as key targets in precision cancer therapy, highlighting oncoprotein addiction and personalized medicine strategies. Understanding ErbB signaling advances biomarker discovery and improves patient treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- ErbB proteins are crucial biomarkers and drug targets in precision cancer therapy.
- They exemplify oncoprotein addiction and personalized medicine principles.
- Understanding ErbB signaling is vital for cancer treatment strategies.
Purpose of the Study:
- To review current knowledge of ErbB proteins in cell signaling and cancer.
- To describe ErbB oncoprotein addiction in various cancer types.
- To highlight technologies for developing predictive cancer models and discuss ErbB-targeted drugs.
Main Methods:
- Literature review of ErbB protein function, signaling, and cancer relevance.
- Analysis of oncoprotein addiction mechanisms in different cancers.
- Evaluation of experimental cancer models and their predictive capabilities.
- Review of ErbB-targeted drugs in clinical trials and routine use.
Main Results:
- ErbB oncoproteins are central to cancer development and therapeutic targeting.
- Oncoprotein addiction to ErbB signaling is a key concept in personalized oncology.
- Innovative cancer models accurately predict ErbB-targeted drug efficacy.
- Genotype-drug response relationships are essential for advancing personalized oncology.
Conclusions:
- Functional characterization of ErbB oncoproteins enhances understanding of predictive biomarkers.
- Oncoprotein addiction and patient stratification are critical for effective cancer treatment.
- Future research using advanced cancer models will identify novel therapeutic strategies and improve clinical outcomes.